‘Pharma Bro’, who drove up anti-HIV drug costs by defrauding investors, gets imprison

The “Pharma Bro” was convicted last year to defraud financial specialists by demonstrating counterfeit record explanations of two failing hedge funds that he ran.

The main drug prices that were used to treat HIV was driven up 50 times by the Martin Shkreli, a previous drug firm executive has been condemned seven-year imprisonment by a New York government court for cheating investors.

The “Pharma Bro” was indicted a year ago to defraud investors by demonstrating counterfeit record explanations of two failing hedge funds that he ran.

As per the PBS reports, the 34-year-old pharmaceutical official, who had gained notoriety for driving up the cost of HIV medicine in 2015 and trolling commentators on the web, cried in the court and apologized to investors and said “I am terribly sorry I lost your trust,” he reportedly said in the court. “You deserve far better.

In spite of the fact that his lawyers requested for tolerance in condemning, the U.S. District Judge Kiyo Matsumoto termed his crimes seriously and handed him the sentence.

Related Posts

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

US market to dent India pharma earnings even as domestic growth remains firm

US market to dent India pharma earnings even as domestic growth remains firm

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg